Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?


No Thumbnail Available
Type
Article
Change log
Authors
Abstract

The management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has come a long way from the first postmortem descriptions of the diseases in the 1930s and 1950s1 Pivotal phases have been the introduction of glucocorticoids (GC) and cyclophosphamide (CYC), the association with ANCA in the 1980s, and consensus classification and nomenclature systems from 1990 onwards2.

Description
Keywords
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antibodies, Antineutrophil Cytoplasmic, Humans
Journal Title
J Rheumatol
Conference Name
Journal ISSN
0315-162X
1499-2752
Volume Title
48
Publisher
The Journal of Rheumatology